MARCHESELLI, Raffaella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.326
EU - Europa 2.992
AS - Asia 2.563
SA - Sud America 372
AF - Africa 83
Continente sconosciuto - Info sul continente non disponibili 82
OC - Oceania 15
Totale 13.433
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.132
GB - Regno Unito 1.312
SG - Singapore 760
CN - Cina 692
IT - Italia 481
HK - Hong Kong 306
BR - Brasile 265
DE - Germania 253
VN - Vietnam 253
SE - Svezia 224
FR - Francia 153
FI - Finlandia 127
RU - Federazione Russa 121
BD - Bangladesh 109
UA - Ucraina 108
CA - Canada 107
IN - India 81
TR - Turchia 74
KR - Corea 53
BG - Bulgaria 43
AR - Argentina 42
ID - Indonesia 40
MA - Marocco 40
IQ - Iraq 30
MX - Messico 25
ES - Italia 22
PL - Polonia 22
BE - Belgio 20
NL - Olanda 19
JP - Giappone 18
PK - Pakistan 17
AE - Emirati Arabi Uniti 16
EC - Ecuador 16
CO - Colombia 15
IE - Irlanda 15
SA - Arabia Saudita 15
ZA - Sudafrica 15
AU - Australia 13
CH - Svizzera 13
CZ - Repubblica Ceca 13
MY - Malesia 12
CR - Costa Rica 11
UZ - Uzbekistan 10
VE - Venezuela 10
AT - Austria 9
IR - Iran 9
AZ - Azerbaigian 8
CL - Cile 8
JM - Giamaica 8
LT - Lituania 8
PH - Filippine 8
TT - Trinidad e Tobago 8
HU - Ungheria 7
DO - Repubblica Dominicana 6
JO - Giordania 6
PY - Paraguay 6
BZ - Belize 5
GP - Guadalupe 5
IL - Israele 5
KE - Kenya 5
KG - Kirghizistan 5
KZ - Kazakistan 5
TH - Thailandia 5
DK - Danimarca 4
GT - Guatemala 4
HN - Honduras 4
PR - Porto Rico 4
TN - Tunisia 4
BO - Bolivia 3
CW - ???statistics.table.value.countryCode.CW??? 3
EG - Egitto 3
EU - Europa 3
LB - Libano 3
NO - Norvegia 3
NP - Nepal 3
PE - Perù 3
PS - Palestinian Territory 3
UY - Uruguay 3
AM - Armenia 2
BH - Bahrain 2
CY - Cipro 2
ET - Etiopia 2
KH - Cambogia 2
MU - Mauritius 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PA - Panama 2
PT - Portogallo 2
QA - Qatar 2
RO - Romania 2
RS - Serbia 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
TZ - Tanzania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
AL - Albania 1
AO - Angola 1
BB - Barbados 1
Totale 13.338
Salva come PNG Salva come JPEG
Città #
Ashburn 1.199
Southend 1.070
Fairfield 592
Santa Clara 556
Singapore 492
Woodbridge 458
Hong Kong 299
Houston 281
San Jose 272
Chandler 269
Seattle 254
Wilmington 223
Ann Arbor 206
Cambridge 205
Jacksonville 203
Beijing 194
Council Bluffs 185
Dearborn 163
Nyköping 162
Hefei 138
New York 125
London 115
Modena 98
Los Angeles 91
Chicago 90
Milan 90
Helsinki 78
Ho Chi Minh City 70
Frankfurt am Main 66
The Dalles 63
San Diego 59
Hanoi 51
Seoul 50
Buffalo 44
Princeton 44
Shanghai 44
Sofia 42
São Paulo 42
Munich 41
Eugene 38
Moscow 36
Columbus 35
Salt Lake City 35
Toronto 34
Casablanca 32
Lauterbourg 32
Izmir 30
Bologna 26
Bremen 26
Jakarta 24
Dallas 23
Montreal 22
Phoenix 21
Rome 21
Brussels 19
Elk Grove Village 19
Denver 18
Warsaw 18
Boardman 17
Da Nang 17
Redwood City 17
Falls Church 16
Orem 16
Tokyo 16
Brooklyn 15
Turku 15
Des Moines 14
Dublin 14
New Delhi 14
Paris 14
Tampa 14
Nanjing 13
Fremont 12
Guangzhou 12
Manchester 12
Washington 12
Atlanta 11
Baghdad 11
Boston 11
North Bergen 11
Poplar 11
Buenos Aires 10
Chennai 10
Dong Ket 10
Kunming 9
Naples 9
Newark 9
Norwalk 9
Ottawa 9
Rho 9
San José 9
Stockholm 9
Dhaka 8
Gurugram 8
Indiana 8
Jeddah 8
San Giuliano Milanese 8
San Mateo 8
Sterling 8
Tashkent 8
Totale 9.714
Salva come PNG Salva come JPEG
Nome #
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 638
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 556
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 480
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 423
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 413
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 409
Body composition and inflammation impact in non-small cell lung cancer patients treated by first-line immunotherapy 402
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 377
A concise review of lenalidomide therapy for follicular lymphoma 366
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 354
Efficacy Controls and Long-Term Follow-Up of Patients (Pts) Treated with FC Plus Rituximab for Relapsed Follicular NHL. Session Type: Publication Only 352
INCIDENCE AND SURVIVAL OF MYELOID MALIGNANCIES IN 1102 PATIENTS IN PROVINCE OF MODENA, NORTHERN ITALY 351
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 350
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 345
The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments 344
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 339
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 337
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 333
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 333
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 328
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 325
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 320
Incidence and outcome of Myelodysplastic Syndromes in province of Modena 316
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma 312
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 308
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 308
Incidence and outcome of chronic myeloproliferative disorders: A population-based study from a cancer registry in northern Italy 302
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts 301
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 299
: Late toxicity and quality of life (QOL) after treatment for Hodgkin disease (HD): A Gruppo Italiano Studio Linfomi (GISL) cohort study on 223 patients 295
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant 289
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 284
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 273
Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL. 268
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 246
Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time 244
Epidemiologia degli infortuni lavorativi in minori: risultati di una indagine condotta nella città di Modena nel periodo gennaio-giugno 2000. 238
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 236
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting 234
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 205
Totale 13.433
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.081
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.081
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022629 0 0 0 0 24 74 49 50 107 61 156 108
2022/2023854 92 111 60 78 98 118 26 87 93 10 55 26
2023/2024683 24 26 49 63 145 59 146 48 17 16 35 55
2024/20251.761 66 19 42 121 373 276 124 108 195 56 140 241
2025/20263.523 241 144 204 385 586 222 446 171 369 368 212 175
2026/20271.373 102 208 341 642 80 0 0 0 0 0 0 0
Totale 13.433